Thrombolytic treatment with tissue plasminogen activator (tPA) in ischemic stroke patients benefits markedly from intravenous administration within 4.5h after symptom onset [55], which relies on early identification of stroke lesions by NCCT scans. The gene discussed is PLAT; the disease is ischemic stroke.